Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials

Costa, Ricardo, Carneiro, Benedito A., Agulnik, Mark, Rademaker, Alfred W., Pai, Sachin G., Villaflor, Victoria M., Cristofanilli, Massimo, Sosman, Jeffrey A. +1 more·2017·Oncotarget
DOI 10.18632/oncotarget.13315

Cited by (123)

Items 101–123 of 123

  1. Retrospective Study of Treatment Patterns and Natural History of Patients with T1a/b N0 Triple-Negative Breast Cancers: A Single-Institution Experience
    Langfeier Liu, Nicholas Lewis, Weihong Sun, Junmin Whiting, Susan J. Hoover, Ricardo Lima Barros Costa · 2023 · Oncology
  2. Nivolumab-induced thyroid dysfunction in patients with lung cancer
    Ana Maria Ramos-Levi, Jacobo Rogado, J.M. Sánchez-Torres, Rámón Colomer, Mónica Marazuela · 2019 · Endocrinología Diabetes y Nutrición (English ed )
  3. How to manage side effects of immunotherapy
    Jindřich Kopecký, Ondřej Kubeček · 2020 · Onkologie
  4. Lung cancer treatment in the era of immunotherapy
    Xu Yang, Liangan Chen · 2020 · Chinese Medical Journal
  5. Image classification of immune checkpoint inhibitor–related pneumonia in lung cancer patients
    Xiaojun Sun, Zhengbo Song, Hongyang Jiang, Yanqing Ma, Ming Chen · 2022 · Clinical Imaging
  6. Cancer Immunotherapy and endocrinology: A new opportunity for multidisciplinary collaboration
    Carles Zafón · 2017 · Endocrinología Diabetes y Nutrición (English ed )
  7. Inmunoterapia oncológica y endocrinología: una nueva oportunidad para la colaboración multidisciplinar
    Carles Zafón · 2017 · Endocrinología Diabetes y Nutrición
  8. Treatment from within: Ductal Carcinoma as an Opportunity to Harness the Immune System
    Justin G. Wilkes, Brian J. Czerniecki, Ricardo Lima Barros Costa · 2020 · Current Breast Cancer Reports
  9. Toxicities of PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Xiangy Kong, Li Chen, Ryan Joseph Sullivan, Zhihong Qi, Yulu Liu, Yi Fang, Lin Zhang, Jing Wang · 2020 · medRxiv
  10. Immuntherapie versus Chemotherapie fortgeschrittener solider Tumoren
    Susanne Krome · 2020 · Onkologische Welt
  11. Usage Patterns and Incidence of Thyroid-related Adverse Events in Patients Treated with PD-1 Inhibitors
    Seoyoung Hwang, Heuijae Kim, Seonyoung Chung, Myungsook Min, Dong‐Churl Suh · 2021 · Korean Journal of Clinical Pharmacy
  12. Causes and Laboratory Investigations of Thyrotoxicosis
    Francesco Latrofa, Paolo Vitti · 2022
  13. Cancer Genomics and Evolution
    William P.D. Hendricks, Aleksandar Sekulić, Alan Haruo Bryce, Muhammed Murtaza, Pilar Ramos, Jessica D. Lang, Timothy G. Whitsett, Timothy K. McDaniel, Russell C. Rockne, Nicholas E. Banovich et al. · 2022 · Wiley eBooks
  14. Immunotherapy and Endocrine Oncology
    Macarena Contreras, Juan Cristóbal Sánchez, Pedro Iglesias · 2022 · Springer eBooks
  15. Immunotherapy and Cancer: The Pharmacists’ Perspective
    Danielle A. Gundrum, Jennifer K Piccolo, Kamal Kant Sahu · 2023 · Springer eBooks
  16. Immunotherapy for Endocrine Oncology
    Macarena Contreras, Juan Cristóbal Sánchez, Pedro Iglesias · 2024 · Springer eBooks
  17. Immunotherapy and Cancer: The Pharmacists’ Perspective
    Danielle A. Gundrum, Jennifer K Piccolo, Kamal Kant Sahu · 2025 · Springer eBooks
  18. Immunotherapy for Endocrine Oncology
    Macarena Contreras, Juan Cristóbal Sánchez, Pedro Iglesias · 2025 · Springer eBooks
  19. Additional file 1 of Thyroid dysfunction in Chinese nasopharyngeal carcinoma after anti-PD-1 therapy and its association with treatment response
    Chen, Zi-Hang, Weihong Zheng, Wu, Chen-Fei, Jia Kou, Yang, Xing-Li, Lin, Li, Jiawei Lv, Sun, Ying, Zhou, Guan-Qun · 2023 · Figshare
  20. Additional file 1 of Comprehensive analysis of T-cell regulatory factors and tumor immune microenvironment in stomach adenocarcinoma
    Wang, Shuchang, Zhang, Weifeng, Wu, Xinrui, Zhu, Zhu, Yuanbiao Chen, Liu, Wangrui, Junnfei Xu, Chen, Li, Chun Zhuang · 2024 · Figshare
  21. Integrating adjuvant therapy as standard multimodal treatment for patients with esophageal cancer after neoadjuvant therapy
    Subin LEE, Andrew Conner, Feredun S. Azari, Monisha Sudarshan, Sudish C. Murthy, Siva Raja · 2026 · Minerva Surgery
  22. Chronic and emerging immune-related adverse events from immune checkpoint inhibitors
    Connor Frey · 2026 · Disease and Therapeutics
  23. Assessing the Impact on Health and Productivity Outcomes of Anti-PD-(L)1 Agents to Treat Early-Stage Cancers in Italy
    Andrea Marcellusi, Fabio Calabrò, Anna Maria Di Giacomo, Fabio Puglisi, Alessio Cortellini, Isobel Thornton, Yan Zhi Tan, Alessandro Catanzaro, Catarina Neves, Fabrizio Ascone et al. · 2026 · Clinical Drug Investigation